Teleflex (TFX) Q4 FY25 earnings call

Teleflex is undergoing a significant transformation, divesting its Acute Care, Interventional Urology, and OEM businesses to create a more focused, higher-growth 'RemainCo' centered on Vascular, Interventional, and Surgical segments. The company plans to deploy $1.8 billion in net proceeds from the divestitures for a $1 billion share repurchase and $800 million in debt repayment, aiming for significantly higher adjusted EPS in 2027 and beyond. While 2026 will be a transition year impacted by $90 million in stranded costs, management is confident in its mid-single-digit revenue growth profile a